Morgan Stanley Raises PT on Halozyme Therapeutics (HALO) to $80 From $75

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best high growth low PE stocks to invest in now. Morgan Stanley raised the firm’s price target on Halozyme Therapeutics, Inc. (NASDAQ:HALO) to $80 from $75 on August 18, keeping an Overweight rating on the shares.

The firm told investors in a research note that the EPS 2025 guidance for Halozyme Therapeutics, Inc. (NASDAQ:HALO) has increased by 20% since January, fueled by its cost discipline and partnered products.

The analyst thus adjusted the firm’s earnings outlook to take into account the raised 2025 base and its implications for future long-term earnings guidance.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical technology platform company that develops, manufactures, and commercializes drug-device combination products through advanced auto-injector technology.

They offer commercial or functional benefits, including increased patient comfort and adherence, and enhanced tolerability and convenience.

While we acknowledge the potential of HALO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.